Skip to main content

Sequenom Signs Exclusive Digital PCR Licensing Agreement with Genomic Nanosystems

NEW YORK (GenomeWeb News) – Sequenom said today that it has obtained exclusive rights to Genomic Nanosystems’ digital PCR technologies and techniques.
 
The agreement gives Sequenom exclusive rights to use the digital PCR methods for non-invasive, prenatal diagnostic testing and sample analysis on any platform. In addition, the company will have exclusive rights to use digital PCR in conjunction with mass spectrometry for all commercial, diagnostic, or research applications except second-generation sequencing.
 
In a statement issued today, Sequenom CEO Harry Stylli said that the agreement — and another digital PCR licensing agreement signed last week — serve to enhance Sequenom’s intellectual property position for non-invasive prenatal diagnostic testing. He also noted that the company plans to develop a system that combines its proprietary MassARRAY system with digital PCR for use in other areas, including the genomic analysis business and cancer research and diagnostics.
 
Financial terms of the agreement were not disclosed.
 
Genomic Nanosystems is a wholly owned subsidiary of Cytonix Corporation.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.